Biofil Chemicals & Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹12.4cr+92.0% on Q1 FY26
Net profit
₹0.1cr−95.5% on Q1 FY26
EBITDA margin
1.1%+1.0 pts on Q1 FY26
EPS
₹0.07−95.3% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue12.46.4+92.0%
EBITDA0.10.0+2,324.1%
EBITDA margin1.1%0.1%+1.0 pts
Profit before tax0.12.8−95.1%
Net profit0.12.4−95.5%
EPS₹0.07₹1.48−95.3%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹12.4 crNet profit₹0.1 crNet margin0.9%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
47.6————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.10.10.10.10.0
3.03.00.50.40.5
50.6————
34.328.433.440.030.0
—−15.0%−16.6%+33.3%—
0.80.60.80.81.2
2.3%2.3%2.5%2.0%3.9%
0.50.40.50.40.7
0.52.80.60.70.6
1.4%9.8%1.7%1.8%1.9%
₹0.30₹1.71₹0.34₹0.44₹0.34
—+399.4%−21.4%+26.6%—
—−0.6−1.92.4−0.1
—−0.2−0.1−0.0−0.0
−0.8−0.8−2.02.4−0.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BIOFILCHEM₹29.26

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMANGALAMVINEETLABLASAORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹47.6 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————47.6
- Cash, Equiv & ST Investments0.00.10.10.10.1
+ Total Debt0.50.40.53.03.0
Enterprise Value————50.6
Revenue30.040.033.428.434.3
Growth %, YoY—+33.3-16.6-15.0—
EBITDA1.20.80.80.60.8
Margin %3.892.042.542.292.29
EBIT0.70.40.50.40.5
Net Income0.60.70.62.80.5
Margin %1.871.771.679.811.41
EPS, Adj (current shares)0.340.440.341.710.30
Growth %, YoY—+26.6-21.4+399.4—
Cash from Operations-0.12.4-1.9-0.6—
Capital Expenditures-0.0-0.0-0.1-0.2—
Free Cash Flow-0.12.4-2.0-0.8-0.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Biofil Chemicals & Pharmaceuticals financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Biofil Chemicals & Pharmaceuticals (NSE: BIOFILCHEM) had a market capitalisation of ₹47.9 crore at the 29 October 2026 close (₹29.41 a share), a PE ratio of 98.9 on the last four quarters' profit and a price-to-book ratio of 2.22. In FY26 its consolidated net profit was ₹2.8 crore on revenue of ₹28.4 crore; in Q1 FY27 (April–June 2026) it was ₹11 lakh, down 95.5% year on year. Its debt-to-equity ratio was 0.14 on 31 March 2026. Promoters held 46.79% of the shares on 30 September 2026.

Share price used
₹29.41 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Biofil Chemicals & Pharmaceuticals at a glance · consolidated

Market cap
₹47.9 Crat ₹29.41 · 29 Oct close
PE ratio (last 4 quarters)
98.917.2 on FY26 profit
Price to book (PB)
2.22book value ₹13.25 a share
ROE (FY26)
13.8%+10.8 pts vs FY25ROCE 1.8%
Debt to equity
0.14net cash ₹31 lakh
Promoter holding
46.79%unchanged vs 30 Jun 202630 September 2026
Net worth
₹21.6 Cr+14.8% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹81 lakh
EPS (FY26)
₹1.71

Questions

What is the Biofil Chemicals & Pharmaceuticals PE ratio today?

Biofil Chemicals & Pharmaceuticals' PE ratio is 98.9 at the 29 October 2026 close (₹29.41 a share): a market capitalisation of ₹47.9 crore divided by consolidated net profit of ₹48 lakh over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹2.8 crore) it is 17.2.

What is the Biofil Chemicals & Pharmaceuticals PB ratio (price to book value)?

Biofil Chemicals & Pharmaceuticals' price-to-book (PB) ratio is 2.22 at the 29 October 2026 close: a market capitalisation of ₹47.9 crore divided by shareholders' equity (book value) of ₹21.6 crore on 31 March 2026. That is a book value of ₹13.25 per share against a share price of ₹29.41.

What is the Biofil Chemicals & Pharmaceuticals net worth?

Biofil Chemicals & Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹21.6 crore on 31 March 2026, up 14.8% from ₹18.8 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹47.9 crore at the 29 October 2026 close.

What is the Biofil Chemicals & Pharmaceuticals market cap?

Biofil Chemicals & Pharmaceuticals' market capitalisation was ₹47.9 crore at the 29 October 2026 close: 1.63 crore shares at ₹29.41 each.

What is the Biofil Chemicals & Pharmaceuticals debt to equity ratio?

Biofil Chemicals & Pharmaceuticals' debt-to-equity ratio was 0.14 on 31 March 2026: borrowings of ₹3 crore against total equity of ₹21.6 crore. A year earlier, on 31 March 2025, it was 0.03.

What is the Biofil Chemicals & Pharmaceuticals EPS?

Biofil Chemicals & Pharmaceuticals' basic earnings per share (EPS) were ₹1.71 in FY26, against ₹0.34 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹0.30.

Is Biofil Chemicals & Pharmaceuticals debt free?

No. Biofil Chemicals & Pharmaceuticals had borrowings of ₹3 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.14. Its cash and current investments were ₹3.3 crore, so it held net cash of ₹31 lakh.

What is the Biofil Chemicals & Pharmaceuticals book value per share?

Biofil Chemicals & Pharmaceuticals' book value per share was ₹13.25 on 31 March 2026: shareholders' equity of ₹21.6 crore divided by the 1.63 crore shares in issue, up 14.8% from ₹11.54 a year earlier. The share price at the 29 October 2026 close was ₹29.41.

What is the Biofil Chemicals & Pharmaceuticals shareholding pattern?

On 30 September 2026, Biofil Chemicals & Pharmaceuticals' shares were held by promoters 46.79%, domestic institutions (DII) 0.08% and retail and other non-institutional investors 53.13%. Over the year, DII holding was unchanged.

What is the Biofil Chemicals & Pharmaceuticals ROE and ROCE?

In FY26, Biofil Chemicals & Pharmaceuticals' return on equity (ROE) was 13.8% and its return on capital employed (ROCE) was 1.8%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 3.0% and ROCE 2.5%.

What is the Biofil Chemicals & Pharmaceuticals free cash flow?

In FY26, Biofil Chemicals & Pharmaceuticals generated ₹60 lakh of cash from operations and spent ₹20 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹81 lakh. In FY25 it was −₹2 crore.

What are the Biofil Chemicals & Pharmaceuticals latest quarterly results?

Biofil Chemicals & Pharmaceuticals' latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit ₹11 lakh, down 95.5% from ₹2.4 crore in Q1 FY26; revenue from operations ₹12.4 crore, up 92.0% year on year.

What is the Biofil Chemicals & Pharmaceuticals promoter holding?

Promoters held 46.79% of Biofil Chemicals & Pharmaceuticals on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Biofil Chemicals & Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), Biofil Chemicals & Pharmaceuticals' consolidated net profit was ₹2.8 crore, up 399.4% from ₹56 lakh in FY25, on revenue from operations of ₹28.4 crore (down 15.0%). Over three years, from FY23, net profit was up 397.1%.

When are the Biofil Chemicals & Pharmaceuticals next results?

Biofil Chemicals & Pharmaceuticals has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does Biofil Chemicals & Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Mangalam Drugs And Organics, Vineet Laboratories and Lasa Supergenerics: Biofil Chemicals & Pharmaceuticals' operating margin of 1.3% is the second highest of the four (Mangalam Drugs And Organics −14.3%, Vineet Laboratories 10.2%, Lasa Supergenerics −136.9%; peer average −47.0%); its return on equity of 13.8% is the highest of the four (Mangalam Drugs And Organics −35.2%, Vineet Laboratories 5.3%, Lasa Supergenerics −51.1%; peer average −27.0%).

Biofil Chemicals & Pharmaceuticals vs Mangalam Drugs And Organics: how do they compare?

In FY26, Biofil Chemicals & Pharmaceuticals earned net profit of ₹2.8 crore on revenue of ₹28.4 crore, against ₹44.4 crore on ₹232 crore for Mangalam Drugs And Organics. Biofil Chemicals & Pharmaceuticals' operating margin was 1.3% (Mangalam Drugs And Organics −14.3%) and its return on equity 13.8% (Mangalam Drugs And Organics −35.2%). At the 29 October 2026 close, Biofil Chemicals & Pharmaceuticals' market capitalisation was ₹47.9 crore against ₹46.3 crore for Mangalam Drugs And Organics.

Where do these Biofil Chemicals & Pharmaceuticals figures come from?

From Biofil Chemicals & Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.